Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

manilatimes.net · 2026-09-14

Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey

TickrTrends take: Veracyte's acquisition of Convergent Genomics expands the competitive landscape in genomic diagnostics, a space where ILMN supplies sequencing technology to multiple players. Given TickrTrends' current overvalued assessment of ILMN, investors should monitor whether such consolidation in diagnostic applications translates into pricing power or volume gains sufficient to justify ILMN's current valuation premium. The continued development of specialized testing platforms by competitors suggests ongoing demand for sequencing infrastructure, though valuation-focused investors may want to assess whether this competitive activity supports ILMN's present pricing multiples in the Healthcare sector.

Read the full story at manilatimes.net →